Dual Adjuvant‐Loaded Peptide Antigen Self‐Assembly Potentiates Dendritic Cell‐Mediated Tumor Immunotherapy
Advanced Science · 2024-09 · 11 (36)
DOI: 10.1002/advs.202403663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.07.2024. Verfasst von Jaehyun Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, Seoul, 04763, Republic of Korea. Hauptthemen laut MEDLINE: Dendritic Cells, Immunotherapy, Adjuvants, Immunologic, Cancer Vaccines. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Brain Korea 21 Fostering Outstanding Universities for Research.
Abstract (Originalsprache)
Clinical translation of current cancer vaccine research has been hampered by limited antitumor immune responses due to inefficient antigen delivery and presentation, suboptimal DC and T cell activation. Biomaterial‐based nanovaccine offers targeted antigen delivery, protection from degradation in vivo, and prolonged tumor therapeutic efficacy. This study introduces a lipid‐coated deoxycholic acid‐survivin nanoassembly (DA‐L‐DSA). Survivin, overexpressed in several cancer cells and involved in cancer cell growth and immune evasion, is selected as a tumor‐associated antigen. An major histocompatibility complex class I binding epitope of survivin is engineered into the nanoassembly. R848, TLR 7/8 agonist, and SD‐208, TGF‐beta receptor1 kinase inhibitor, are coencapsulated into the nanoassembly as potent adjuvants to boost DC maturation and enhance antigen presentation. The DA‐L‐DSA effectively stimulates the maturation of dendritic cells, migrates into lymph nodes, and enhances T‐cell activation and Th1 response. A substantial influx of cytotoxic T lymphocytes into primary tumors is observed in a murine melanoma model and demonstrates anti‐metastatic effects in a spontaneous breast cancer metastasis model. Furthermore, DA‐L‐DSA exhibits a remarkable synergistic effect in the combination therapy with immune checkpoint inhibitors alleviating immunosuppressive tumor microenvironment. Taken together, these findings suggest DA‐L‐DSA as a promising immuno‐therapeutic platform that could be applicable to diverse intractable cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research, Hanyang University, Seoul, 04763, Republic of Korea.
- Nucleic Acid Therapeutics Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Chungcheongbuk-do, 28116, Republic of Korea.
- Cursus Bio Inc. Icure Tower, Seoul, 06170, Republic of Korea.
- Institute for Bioengineering and Biopharmaceutical Research (IBBR), Hanyang University, Seoul, 04763, Republic of Korea.
ORCID-Profile: Yong-Hee Kim
Förderung
- National Research Foundation of Korea
- Brain Korea 21 Fostering Outstanding Universities for Research
Zitieren
APA
Kim, J., Kang, S., Kim, J., Yong, S. B., Lahiji, S. F., & Kim, Y. H. (2024). Dual Adjuvant‐Loaded Peptide Antigen Self‐Assembly Potentiates Dendritic Cell‐Mediated Tumor Immunotherapy. Advanced Science, 11(36). https://doi.org/10.1002/advs.202403663
Vancouver
Kim J, Kang S, Kim J, Yong SB, Lahiji SF, Kim YH. Dual Adjuvant‐Loaded Peptide Antigen Self‐Assembly Potentiates Dendritic Cell‐Mediated Tumor Immunotherapy. Advanced Science. 2024;11(36). doi:10.1002/advs.202403663
BibTeX
@article{Kim2024,
author = {Kim, Jaehyun and Kang, Seyoung and Kim, Jisu and Yong, Seok-Beom and Lahiji, Shayan Fakhraei and Kim, Yong-Hee},
title = {Dual Adjuvant‐Loaded Peptide Antigen Self‐Assembly Potentiates Dendritic Cell‐Mediated Tumor Immunotherapy},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {36},
doi = {10.1002/advs.202403663}
}
EUVIMED